Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau targeted vaccines (ACI-35.030, JACI-35.054) in early Alzheimer's Disease
NCT04445831Phase 2Completed
- Sponsor
- AC Immune SA
- Start
- Jul 2019
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Targeted Liposomes, Split/Subunit Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of ACI-35.030, JACI-35.054 in Alzheimer's disease (AD), sponsored by AC Immune SA. Started Jul 2019; status: completed.
02
Drugs
ACI-35.030JACI-35.054
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04445831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445831.